智通财经网·2026-02-04 09:39Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory, received a Drug Registration Certificate from the National Medical Products Administration for the production of Sitagliptin Metformin Extended-Release Tablets, which are intended for adult patients with type 2 diabetes who are undergoing combined treatment with Sitagliptin and Metformin Extended-Release Tablets [1] Group 1 - The drug Sitagliptin Metformin Extended-Release Tablets is approved for production and is specifically for adult patients with type 2 diabetes [1] - The drug was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1] - The application for registration and market launch was submitted to the National Medical Products Administration in June 2024 and has been accepted [1] Group 2 - The company has invested approximately RMB 8.49 million in research and development for this drug as of the date of the announcement [1]